Payment overview · 2025
General Payments
$1,662.64
62 reported records · 12 companies
Healthcare provider profile · identity verified
Rosa Calderon, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · UNION CITY, NJ · NPI 1750497129
Verified facts
What the public records show
CMS Open Payments records show Rosa Calderon, M.D. received $1,662.64 in general payments during 2025 across 62 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess, Mounjaro, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 375 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 289 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 289 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trulicity by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $432.13 | 26.0% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $334.64 | 20.1% | 18 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $259.23 | 15.6% | 12 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $166.54 | 10.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $161.07 | 9.7% | 11 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $125.00 | 7.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.08 | 3.2% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $53.35 | 3.2% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $30.54 | 1.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.66 | 1.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.40 | 0.9% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $14.00 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,662.64 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $450.59 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $285.02 | 15 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $259.23 | 12 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $166.54 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $166.54 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $92.01 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $80.59 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.06 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $53.35 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $50.41 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $30.54 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| BREKIYA Normalized: brekiya |
Drug | Amneal Pharmaceuticals LLC | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 206 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 145 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 289 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 375 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 224 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
206 | 35 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
375 | 81 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
145 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
109 | 46 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
289 | 48 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
289 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
90 | 14 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
161 | 40 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
224 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 465 | 72 |
| Omeprazole | Omeprazole | 443 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 414 | 82 |
| Diclofenac Sodium | Diclofenac Sodium | 394 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 388 | 52 |
| Linzess | Linaclotide | 375 | 81 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 359 | 58 |
| Ibuprofen | Ibuprofen | 356 | 69 |
| Metformin Hcl | Metformin Hcl | 345 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 319 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 300 | 67 |
| Ozempic | Semaglutide | 300 | 41 |
| Zileuton Er | Zileuton | 290 | 31 |
| Jardiance | Empagliflozin | 289 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 277 | 51 |
| Calcipotriene | Calcipotriene | 268 | 48 |
| Acyclovir | Acyclovir | 263 | 32 |
| Clobetasol Propionate | Clobetasol Propionate | 251 | 30 |
| Mometasone Furoate | Mometasone Furoate | 243 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 243 | 44 |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 238 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 238 | 47 |
| Vascepa | Icosapent Ethyl | 235 | 44 |
| Azithromycin | Azithromycin | 224 | 103 |
| Xifaxan | Rifaximin | 224 | 50 |
| Naftifine Hcl | Naftifine Hcl | 221 | 24 |
| Mupirocin | Mupirocin Calcium | 220 | 31 |
| Albuterol Sulfate | Albuterol Sulfate | 206 | 28 |
| Creon | Lipase/Protease/Amylase | 206 | 35 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 206 | 30 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 201 | 53 |
| Meloxicam | Meloxicam | 200 | 47 |
| Restasis | Cyclosporine | 198 | 85 |
| Fluticasone Propionate | Fluticasone Propionate | 192 | 70 |
| Gabapentin | Gabapentin | 186 | 35 |
| Glimepiride | Glimepiride | 183 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 183 | 42 |
| Lisinopril | Lisinopril | 171 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 168 | 29 |
| Simvastatin | Simvastatin | 166 | 29 |
| Trulance | Plecanatide | 161 | 40 |
| Nifedipine Er | Nifedipine | 160 | 33 |
| Celecoxib | Celecoxib | 158 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 156 | 25 |
| Lidocaine | Lidocaine | 152 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 147 | 50 |
| Farxiga | Dapagliflozin Propanediol | 145 | 34 |
| Ketoconazole | Ketoconazole | 132 | 27 |
| Trazodone Hcl | Trazodone Hcl | 132 | 23 |
| Ammonium Lactate | Ammonium Lactate | 131 | 21 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 131 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 127 | 21 |
| Alendronate Sodium | Alendronate Sodium | 126 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 125 | 27 |
| Januvia | Sitagliptin Phosphate | 124 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 122 | 22 |
| Montelukast Sodium | Montelukast Sodium | 122 | 21 |
| Tramadol Hcl | Tramadol Hcl | 115 | 22 |
| Naproxen Sodium | Naproxen Sodium | 114 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 109 | 29 |
| Famotidine | Famotidine | 109 | 28 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 109 | 21 |
| Lokelma | Sodium Zirconium Cyclosilicate | 109 | 46 |
| Losartan Potassium | Losartan Potassium | 108 | 22 |
| Niacin | Niacin | 107 | 18 |
| Furosemide | Furosemide | 106 | 17 |
| Hydrocortisone | Hydrocortisone | 105 | 23 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 103 | 17 |
| Eliquis | Apixaban | 100 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 22 |
| Promethazine Hcl | Promethazine Hcl | 91 | 25 |
| Clindamycin Phosphate | Clindamycin Phosphate | 90 | 17 |
| Lansoprazole | Lansoprazole | 90 | 16 |
| Naproxen | Naproxen | 90 | 23 |
| Trulicity | Dulaglutide | 90 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 86 | 19 |
| Procto-Med Hc | Hydrocortisone | 84 | 25 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 82 | 17 |
| Prednisone | Prednisone | 82 | 27 |
| Meclizine Hcl | Meclizine Hcl | 81 | 23 |
| Donepezil Hcl | Donepezil Hcl | 80 | 22 |
| Megestrol Acetate | Megestrol Acetate | 75 | 12 |
| Clonidine Hcl | Clonidine Hcl | 74 | 16 |
| Halobetasol Propionate | Halobetasol Propionate | 73 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 73 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | suppressed |
| Sucralfate | Sucralfate | 67 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 66 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 65 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 64 | 11 |
| Clotrimazole | Clotrimazole | 64 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 64 | 14 |
| Dificid | Fidaxomicin | 63 | 46 |
| Jublia | Efinaconazole | 59 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 58 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 57 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 15 |
| Memantine Hcl | Memantine Hcl | 53 | 12 |
| Ciclopirox | Ciclopirox | 52 | 14 |
| Azelaic Acid | Azelaic Acid | 49 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 49 | 14 |
| Silver Sulfadiazine | Silver Sulfadiazine | 49 | 15 |
| Olanzapine | Olanzapine | 48 | suppressed |
| Finasteride | Finasteride | 46 | 14 |
| Proctozone-Hc | Hydrocortisone | 46 | 14 |
| Lactulose | Lactulose | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 13 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 44 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 16 |
| Icosapent Ethyl | Icosapent Ethyl | 44 | 25 |
| Levetiracetam | Levetiracetam | 44 | suppressed |
| Mupirocin | Mupirocin | 44 | 21 |
| Carvedilol | Carvedilol | 43 | 14 |
| Brilinta | Ticagrelor | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 25 |
| Enalapril Maleate | Enalapril Maleate | 40 | 11 |
| Epinephrine | Epinephrine | 40 | 14 |
| Fluocinonide | Fluocinonide | 39 | 12 |
| Metformin Er Gastric | Metformin Hcl | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 28 |
| Atenolol | Atenolol | 37 | suppressed |
| Enulose | Lactulose | 37 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 35 | 12 |
| Amoxicillin | Amoxicillin | 34 | 18 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 34 | 13 |
| Nitroglycerin | Nitroglycerin | 34 | suppressed |
| Premarin | Estrogens, Conjugated | 34 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 34 | 28 |
| Clemastine Fumarate | Clemastine Fumarate | 33 | suppressed |
| Pregabalin | Pregabalin | 32 | 13 |
| Sertraline Hcl | Sertraline Hcl | 32 | suppressed |
| Cyclosporine | Cyclosporine | 31 | 20 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 31 | 17 |
| Lorazepam | Lorazepam | 31 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 30 | 21 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 29 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Metronidazole | Metronidazole | 28 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 22 | suppressed |
| Enstilar | Calcipotriene/Betamethasone | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Lumigan | Bimatoprost | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Permethrin | Permethrin | 20 | suppressed |
| Promacta | Eltrombopag Olamine | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 20 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 19 | 19 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Prolensa | Bromfenac Sodium | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | 12 |
| Mesalamine | Mesalamine | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 16 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Desoximetasone | Desoximetasone | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tobradex | Tobramycin/Dexamethasone | 12 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 12 | suppressed |
| Darunavir | Darunavir | 11 | 11 |
| Glipizide Er | Glipizide | 11 | suppressed |
| Imiquimod | Imiquimod | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Risperidone Odt | Risperidone | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,662.64 · 62 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, BREKIYA, BREZTRI, CREON, CT THROMBECTOMY SYSTEM KIT, DATROWAY, FARXIGA, FLOWTRIEVER CATHETER, S, IBSRELA, JARDIANCE, LINZESS, MOUNJARO, QULIPTA, REXULTI, UBRELVY, VRAYLAR, Vest Therapy Und, XIFAXAN, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error